173459-53-5

Basic information

• Product Name: 1H-Indazole-1-carboxylic acid, 7-aMino-, 1,1-diMethylethyl ester
• Synonyms: 1H-Indazole-1-carboxylic acid, 7-aMino-, 1,1-diMethylethyl ester
• CAS NO: 173459-53-5
• Molecular Formula: C12H15N3O2
• Molecular Weight: 233.2664
• Mol File: 173459-53-5.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-Indazole-1-carboxylic acid, 7-aMino-, 1,1-diMethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Indazole-1-carboxylic acid, 7-aMino-, 1,1-diMethylethyl ester(173459-53-5)
• EPA Substance Registry System: 1H-Indazole-1-carboxylic acid, 7-aMino-, 1,1-diMethylethyl ester(173459-53-5)

Safety Data

• Hazardous Substances Data: 173459-53-5(Hazardous Substances Data)

Usage

General Description

1H-Indazole-1-carboxylic acid, 7-amino-, 1,1-dimethylethyl ester is a chemical compound with the molecular formula C14H18N4O2. It is an ester derivative of 1H-indazole-1-carboxylic acid, an indazole compound with potential pharmaceutical applications. This particular compound is often used as a building block in the synthesis of various pharmaceutical agents and drug candidates. It has shown potential as an inhibitor of certain enzymes and has been studied for its potential use in the treatment of various diseases and conditions. Additionally, it is important to handle this compound with care and adhere to proper safety protocols when working with it in a laboratory setting.

Upstream product

• 173459-52-4 1-N-Boc-7-nitroindazole 

Relevant articles and documents

METHOD OF INDUCING CHOLECYSTOKININ AGONIST ACTIVITY USING 1,4-BENZODIAZEPINE COMPOUNDS

A method of inducing a Cholescystokinin-A receptor agonist response in a mammal by administering a compound of formula (I), STR1 where R 1 is C 1-C 6 alkyl, C 3-6 cycloalkyl, phenyl, or substituted phenyl; R 2 is C 3-6 alkyl, C 3-6 cycloalkyl, C 3-6 alkenyl, benzyl, phenylC 1-3 alkyl or substituted phenyl; or NR 1 R 2 together form 1,2,3,4-tetrahydroquinoline or benzazepine mono-, di-, or trisubstituted independently with C 1-6 alkyl, C 1-6 alkoxy or halogen substituents; n is an integer selected from the grouping consisting of 0, 1,2 or 3; p is the integer 0 or 1; q is the integer 0 or 1; r is the integer 0 or 1, provided that when q is 0 then r is 0; R 3, R 4, R 5 and R 8 are selected from a variety of substituents; X is nitrogen, nitroso or R 8 ; m is an integer selected from the group consisting of 0, 1, 2 or 3; Y and Z are hydrogen or halogen, novel intermediates, a pharmaceutical composition for treating obesity, gall bladder stasis, disorders of pancreatic secretion, methods for such treatment and processes for preparing compounds of formula (I).